---
title: "Forms Syntron released its performance for the first half of the year, with a net profit attributable to the parent company of 43.9648 million yuan, an increase of 19.46%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255058002.md"
description: "Forms Syntron released its 2025 semi-annual report, with operating revenue of 307 million yuan, a year-on-year decrease of 10.37%. The net profit attributable to shareholders of the listed company was 43.9648 million yuan, a year-on-year increase of 19.46%; the net profit excluding non-recurring gains and losses was 44.1142 million yuan, a year-on-year increase of 25.32%. The basic earnings per share were 0.0829 yuan"
datetime: "2025-08-28T16:27:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255058002.md)
  - [en](https://longbridge.com/en/news/255058002.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255058002.md)
generator: "portal-rs"
---

# Forms Syntron released its performance for the first half of the year, with a net profit attributable to the parent company of 43.9648 million yuan, an increase of 19.46%

According to the Zhitong Finance APP, Forms Syntron (300468.SZ) released its semi-annual report for 2025, reporting an operating income of 307 million yuan, a year-on-year decrease of 10.37%. The net profit attributable to shareholders of the listed company was 43.9648 million yuan, a year-on-year increase of 19.46%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 44.1142 million yuan, a year-on-year increase of 25.32%. The basic earnings per share were 0.0829 yuan

### Related Stocks

- [300468.CN](https://longbridge.com/en/quote/300468.CN.md)

## Related News & Research

- [HM Exploration shares gain DTC eligibility for US trading on OTCQB](https://longbridge.com/en/news/296448374.md)
- [Algorand: v5 Mainnet goes live - 22 Aug 2026](https://longbridge.com/en/news/296687546.md)
- [NexgenRx Announces Second Quarter Results (With Substantial Increases in Revenue, EBITDA and Financial Position) and Declaration of Dividend](https://longbridge.com/en/news/296536656.md)
- [Vector Science files US provisional patent for orthopedic tissue-regeneration peptide platform](https://longbridge.com/en/news/296483037.md)
- [PZU: Solid revenue and profit growth, strong capital, and strategic expansion drive robust results](https://longbridge.com/en/news/296436534.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**